Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Research Question:
Does the drug Seralutinib improve the exercise capacity of people with Pulmonary Arterial
Hypertension (PAH)?
Basic Study Information
Purpose:
Seralutinib is an inhaled medication for PAH. Participants with PAH age 18-75 and
a BMI of 17-40 may be eligible to participate. Participants will be randomized to
either placebo or drug. The duration of the study is up to a maximum of 48 weeks.
Location: University of Rochester Medical Center
Study Reference #: STUDY00008886
Lead Researcher (Principal Investigator)
Lead Researcher:
R White, III
Study Contact Information
Study Coordinator: GB002, Inc.
Email: ClinicalTrials@gossamerbio.com
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search